SOFIA, BULGARIA / ACCESS Newswire / March 7, 2025 / The memecoin market has proven that virality and community engagement can turn simple tokens into global sensations. But while most memecoins ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Beyond (BYON) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.22 per share a year ago. These figures are ...

Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session ...

Shares of BYON opened at $5.53 on Wednesday. The firm has a market capitalization of $294.10 million, a P/E ratio of -0.75 and a beta of 3.91. Beyond has a 12-month low of $4.45 and a 12-month ...

NYSE:BYON opened at $7.64 on Friday. The company has a quick ratio of 0.91, a current ratio of 0.97 and a debt-to-equity ratio of 0.17. The company has a market cap of $351.59 million, a P/E ratio ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...